Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Affimed N.V.
  6. News
  7. Summary
    AFMD   NL0010872420

AFFIMED N.V.

(AFMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Affimed N : Jefferies London Healthcare Conference 2021 - Virtual

11/16/2021 | 07:07pm EST
Jefferies London Healthcare Conference 2021 - Virtual
Presenter

Dr. Adi Hoess, CEO

Date

November 18, 2021

Time

8:00 a.m. GMT / 3:00 a.m. EST

Disclaimer

Affimed NV published this content on 18 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 November 2021 00:06:03 UTC.


ę Publicnow 2021
All news about AFFIMED N.V.
01/06AFFIMED N : Announces Completion of Enrollment in REDIRECT, the Registration-Directed Stud..
PU
01/06Affimed Completes Enrollment in Phase 2 Lymphoma Trial; Gets FDA Nod for Another AFM13 ..
MT
01/06Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study..
GL
01/06Affimed N.V. Announces Completion of Enrollment in Redirect, the Registration-Directed ..
CI
01/05Affimed to Present at the 40th Annual J.P. Morgan Healthcare Conference
GL
2021Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd Ame..
AQ
2021AFFIMED N : Press Release dated December 9, 2021 - Form 6-K
PU
2021Affimed N.V. to Discuss Treatment of Cd30-Positive Lymphoma Patients with Cord Blood-De..
CI
2021Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymph..
AQ
2021Affimed Starts Patient Enrolment for Study to Evaluate Combination Treatment Targeting ..
MT
More news
Analyst Recommendations on AFFIMED N.V.
More recommendations
Financials
Sales 2021 38,2 M 42,8 M 42,8 M
Net income 2021 -56,0 M -62,7 M -62,7 M
Net cash 2021 172 M 193 M 193 M
P/E ratio 2021 -7,46x
Yield 2021 -
Capitalization 436 M 490 M 488 M
EV / Sales 2021 6,90x
EV / Sales 2022 7,06x
Nbr of Employees 153
Free-Float 97,3%
Chart AFFIMED N.V.
Duration : Period :
Affimed N.V. Technical Analysis Chart | AFMD | NL0010872420 | MarketScreener
Technical analysis trends AFFIMED N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,54 €
Average target price 11,61 €
Spread / Average Target 228%
EPS Revisions
Managers and Directors
Adolf Hoess Chief Commercial Officer
Angus W. Smith Chief Financial Officer
Thomas O. Hecht Chairman-Supervisory Board
Andreas Harstrick Chief Medical Officer
Arndt Schottelius Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
AFFIMED N.V.-27.90%490
GILEAD SCIENCES, INC.-7.26%84 470
REGENERON PHARMACEUTICALS-4.16%63 282
VERTEX PHARMACEUTICALS3.18%57 608
WUXI APPTEC CO., LTD.-12.11%47 873
BIONTECH SE-37.66%38 812